NLS Pharmaceutics AG (NLSP)
NASDAQ: NLSP · Real-Time Price · USD
2.030
-0.040 (-1.93%)
Jan 14, 2025, 4:00 PM EST - Market closed
NLS Pharmaceutics AG Employees
As of December 31, 2021, NLS Pharmaceutics AG had 7 total employees, including 6 full-time and 1 part-time employees.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$942,161
Market Cap
3.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2021 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
NLSP News
- 6 days ago - NLS Pharmaceutics Ltd. and Kadimastem Ltd. - PRNewsWire
- 26 days ago - NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - Accesswire
- 4 weeks ago - NLS Pharmaceutics CEO Issues Letter to Shareholders - Accesswire
- 5 weeks ago - NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market - PRNewsWire
- 6 weeks ago - NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - Accesswire
- 2 months ago - NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - Accesswire
- 2 months ago - NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - Accesswire
- 2 months ago - NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements - Accesswire